Androgen receptor phosphorylation at serine 81 and serine 213 in castrate-resistant prostate cancer-Reference-Cited by-同舟云学术

Androgen receptor phosphorylation at serine 81 and serine 213 in castrate-resistant prostate cancer

Published:2020-05-01 Issue:4 Volume:23 Page:596-606
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

McAllister Milly J.^ORCID,McCall Pamela,Dickson Ashley,Underwood Mark A.,Andersen Ditte,Holmes Elizabeth,Markert Elke,Leung Hing Y.^ORCID,Edwards Joanne^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Urology,Oncology

Link

http://www.nature.com/articles/s41391-020-0235-1.pdf

Reference41 articles.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.

2. Tilki D, Schaeffer EM, Evans CP. Understanding mechanisms of resistance in metastatic castration-resistant prostate cancer: the role of the androgen receptor. Eur Urol Focus. 2016;2:499–505.

3. Ponguta LA, Gregory CW, French FS, Wilson EM. Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer. J Biol Chem. 2008;283:20989–1001.

4. Hsu FN, Chen MC, Chiang MC, Lin E, Lee YT, Huang PH, et al. Regulation of androgen receptor and prostate cancer growth by cyclin-dependent kinase 5. J Biol Chem. 2011;286:33141–9.

5. Górowska-Wójtowicz E, Hejmej A, Kamińska A, Pardyak L, Kotula-Balak M, Dulińska-Litewka J, et al. Anti-androgen 2-hydroxyflutamide modulates cadherin, catenin and androgen receptor phosphorylation in androgen-sensitive LNCaP and androgen-independent PC3 prostate cancer cell lines acting via PI3K/Akt and MAPK/ERK1/2 pathways. Toxicol Vitr. 2017;40:324–35.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of protein post-translational modifications in prostate cancer;PeerJ;2024-08-12

2. Androgen‐repressed lncRNA LINC01126 drives castration‐resistant prostate cancer by regulating the switch between O‐GlcNAcylation and phosphorylation of androgen receptor;Clinical and Translational Medicine;2024-01

3. Newly developed preclinical models reveal broad‐spectrum CDK inhibitors as potent drugs for CRPC exhibiting primary resistance to enzalutamide;Cancer Science;2023-11-03

4. Mitogen-Activated Protein Kinase and Nuclear Hormone Receptor Crosstalk in Cancer Immunotherapy;International Journal of Molecular Sciences;2023-09-04

5. Phosphorylation of nuclear receptors: Novelty and therapeutic implications;Pharmacology & Therapeutics;2023-08